News

If successful, guanabenz (formerly called MRF-008) could be the first MS treatment to focus on protecting myelin from damage, which is the hallmark of MS, rather than on

The orphan designation is held by the company’s European agent, Biological Consulting Europe, which is located in the UK. Advanced Inhalation Therapies chief medical officer Dr David Greenberg

Cynviloq, which is marketed as Genexol-PM in South Korea, is the company’s next-generation nanoparticle paclitaxel and it completed patient enrollment in the Tribeca registrational trial in January. Sorrento,

Amerigen believes that it is a first applicant to file an ANDA for Toviaz containing a Paragraph IV certification, under the provisions of the Hatch-Waxman Act. In the

The acquisition of this product will help the company focus beyond addiction and pain to include schizophrenia and other serious psychiatric disorders. With the acquisition of risperidone, Braeburn

Tuzistra XR is an extended-release oral suspension combination of codeine and chlorpheniramine indicated for oral use for relief of cough and symptoms associated with upper respiratory allergies or

Results from the multicenter, randomized, placebo controlled Phase III trial (MDS-005) showed that significantly more patients treated with lenalidomide achieved red-blood-cell-transfusion independence (RBC-TI) of at least 56 days

Under the deal, PeptiDream will use its peptide discovery platform system (PDPS) technology to produce macrocylic/constrained peptides against multiple targets of interest selected by Merck. Merck will have

"We have already seen good evidence that Luminate can induce PVD in patients with diabetic macular edema," says Baruch Kuppermann, M.D., Ph.D., Professor of Ophthalmology and Biomedical Engineering,